Cargando…

Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium

BACKGROUND: Serious lower respiratory tract infections (SLRTIs), especially Streptococcus pneumoniae (SP)-related pneumonia cause considerable morbidity and mortality. Chest imaging, sputum and blood culture are not routinely obtained by general practitioners (GPs). Antibiotic therapy is usually sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Flamaing, Johan, De Backer, Wilfried, Van Laethem, Yves, Heijmans, Stéphane, Mignon, Annick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443659/
https://www.ncbi.nlm.nih.gov/pubmed/26012956
http://dx.doi.org/10.1186/s12875-015-0282-1
_version_ 1782373033492611072
author Flamaing, Johan
De Backer, Wilfried
Van Laethem, Yves
Heijmans, Stéphane
Mignon, Annick
author_facet Flamaing, Johan
De Backer, Wilfried
Van Laethem, Yves
Heijmans, Stéphane
Mignon, Annick
author_sort Flamaing, Johan
collection PubMed
description BACKGROUND: Serious lower respiratory tract infections (SLRTIs), especially Streptococcus pneumoniae (SP)-related pneumonia cause considerable morbidity and mortality. Chest imaging, sputum and blood culture are not routinely obtained by general practitioners (GPs). Antibiotic therapy is usually started empirically. The BinaxNOW® and Urine Antigen Detection (UAD) assays have been developed respectively to detect a common antigen from all pneumococcal strains and the 13 pneumococcal serotypes present in the vaccine Prevenar 13® (PCV13). METHODS: OPUS-B was a multicentre, prospective, case-control, observational study of patients with SLRTI in primary care in Belgium, conducted during two winter seasons (2011–2013). A urine sample was collected at baseline for the urine assays. GPs were blinded to the results. All patients with a positive BinaxNOW® test and twice as much randomly selected BinaxNOW® negative patients were followed up. Recorded data included: socio-demographics, medical history, vaccination history, clinical symptoms, CRB-65 score, treatments, hospitalization, blood cultures, healthcare use, EQ-5D score. The objectives were to evaluate the percentage of SP SLRTI within the total number of SLRTIs, to assess the percentage of SP serotypes and to compare the burden of disease between pneumococcal and non-pneumococcal SLRTIs. RESULTS: There were 26 patients with a BinaxNOW® positive test and 518 patients with a BinaxNOW® negative test. The proportion of pneumococcal SLRTI was 4.8 % (95 % CI: 3.1 %–7.2 %). Sixty-eight percent of positive cases showed serotypes represented in PCV13. In the BinaxNOW-positive patients, women were more numerous, there was less exposure to young children, seasonal influenza vaccination was less frequent, COPD was more frequent, the body temperature and the number of breaths per minute were higher, the systolic blood pressure was lower, the frequency of sputum, infiltrate, chest pain, muscle ache, confusion/disorientation, diarrhoea, pneumonia and exacerbations of COPD was more frequent, EQ-5D index and VAS scale were lower, the number of visits to the GP, of working days lost and of days patients needed assistance were higher. CONCLUSIONS: SP was responsible for approximately 5 % of SLRTIs observed in primary care in Belgium. Pneumococcal infection was associated with a significant increase in morbidity. Sixty-eight percent of serotypes causing SLRTI were potentially preventable by PCV13.
format Online
Article
Text
id pubmed-4443659
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44436592015-05-27 Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium Flamaing, Johan De Backer, Wilfried Van Laethem, Yves Heijmans, Stéphane Mignon, Annick BMC Fam Pract Research Article BACKGROUND: Serious lower respiratory tract infections (SLRTIs), especially Streptococcus pneumoniae (SP)-related pneumonia cause considerable morbidity and mortality. Chest imaging, sputum and blood culture are not routinely obtained by general practitioners (GPs). Antibiotic therapy is usually started empirically. The BinaxNOW® and Urine Antigen Detection (UAD) assays have been developed respectively to detect a common antigen from all pneumococcal strains and the 13 pneumococcal serotypes present in the vaccine Prevenar 13® (PCV13). METHODS: OPUS-B was a multicentre, prospective, case-control, observational study of patients with SLRTI in primary care in Belgium, conducted during two winter seasons (2011–2013). A urine sample was collected at baseline for the urine assays. GPs were blinded to the results. All patients with a positive BinaxNOW® test and twice as much randomly selected BinaxNOW® negative patients were followed up. Recorded data included: socio-demographics, medical history, vaccination history, clinical symptoms, CRB-65 score, treatments, hospitalization, blood cultures, healthcare use, EQ-5D score. The objectives were to evaluate the percentage of SP SLRTI within the total number of SLRTIs, to assess the percentage of SP serotypes and to compare the burden of disease between pneumococcal and non-pneumococcal SLRTIs. RESULTS: There were 26 patients with a BinaxNOW® positive test and 518 patients with a BinaxNOW® negative test. The proportion of pneumococcal SLRTI was 4.8 % (95 % CI: 3.1 %–7.2 %). Sixty-eight percent of positive cases showed serotypes represented in PCV13. In the BinaxNOW-positive patients, women were more numerous, there was less exposure to young children, seasonal influenza vaccination was less frequent, COPD was more frequent, the body temperature and the number of breaths per minute were higher, the systolic blood pressure was lower, the frequency of sputum, infiltrate, chest pain, muscle ache, confusion/disorientation, diarrhoea, pneumonia and exacerbations of COPD was more frequent, EQ-5D index and VAS scale were lower, the number of visits to the GP, of working days lost and of days patients needed assistance were higher. CONCLUSIONS: SP was responsible for approximately 5 % of SLRTIs observed in primary care in Belgium. Pneumococcal infection was associated with a significant increase in morbidity. Sixty-eight percent of serotypes causing SLRTI were potentially preventable by PCV13. BioMed Central 2015-05-27 /pmc/articles/PMC4443659/ /pubmed/26012956 http://dx.doi.org/10.1186/s12875-015-0282-1 Text en © Flamaing et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Flamaing, Johan
De Backer, Wilfried
Van Laethem, Yves
Heijmans, Stéphane
Mignon, Annick
Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title_full Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title_fullStr Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title_full_unstemmed Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title_short Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
title_sort pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in belgium
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443659/
https://www.ncbi.nlm.nih.gov/pubmed/26012956
http://dx.doi.org/10.1186/s12875-015-0282-1
work_keys_str_mv AT flamaingjohan pneumococcallowerrespiratorytractinfectionsinadultsanobservationalcasecontrolstudyinprimarycareinbelgium
AT debackerwilfried pneumococcallowerrespiratorytractinfectionsinadultsanobservationalcasecontrolstudyinprimarycareinbelgium
AT vanlaethemyves pneumococcallowerrespiratorytractinfectionsinadultsanobservationalcasecontrolstudyinprimarycareinbelgium
AT heijmansstephane pneumococcallowerrespiratorytractinfectionsinadultsanobservationalcasecontrolstudyinprimarycareinbelgium
AT mignonannick pneumococcallowerrespiratorytractinfectionsinadultsanobservationalcasecontrolstudyinprimarycareinbelgium